BIOSIMILAR COMPARABILITY STUDIES
Kymos is a GMP-certified an EMA and FDA inspected CRO offering full biosimilar comparability studies. Releasing biosimilar drugs to the market is extremely challenging and calls for well-equipped laboratories able to conduct all assays, ensuring purity, identity and potency as well as GMP certifications and manufacturing authorizations, subject to periodic inspections by regulatory bodies such as the FDA and the EMA. We follow a step-by-step comparability model for biosimilar drugs focused on critical quality attributes (CQAs), identified and classified according to their risk ranking. The number and nature of required assays is determined from the list below on a case-by-case basis:

GENERAL ANALYTICAL TECHNIQUES | STRUCTURAL ANALYSIS |
---|---|
A preliminary overview of the quality attributes of the molecule during initial development phases:
| Full molecular identification for strain selection, bioprocess and final product characterization:
|
CONFORMATIONAL ANALYSIS | IDENTITY, CONTENT, PROTEIN IMPURITIES |
Protein folding and 3D conformation determine biological activity and immunogenicity:
| Chromatographic patterns are quality indicators of the purification process:
|
PROCESS-RELATED IMPURITIES | BIOLOGICAL ACTIVITY |
Other quality indicators of the purification process and also linked to safety concerns:
| Biological tests to confirm molecule activity:
|
Related Services
Congrès France Bioproduction
Paris, F or online | 7-8 April 2022 | Booth #24
Swiss Biotech Days
Basel, CH | 2-3 May 2022 | Booth #44
Journées POLEPHARMA du Biotesting
Evreux, F | 1-2 June 2022 | Booth #23
AFI Symposium
Rimini, IT | 08-09 Jun 2022 | Booth #17
farmaforum
Madrid, E | 5-6 October 2022 | Booth G42
CPHI 2022
Frankfurt, DE | 01-03 Nov 2022 | Booth 41L60